Crowley’s vision for BIO; plus MASH & CAR Ts — a BioCentury podcast

Madrigal prepares to launch its MASH drug. BCMA-directed CAR Ts go before FDA’s ODAC

Putting patients at center stage is at the core of John Crowley’s vision for BIO as he begins his tenure leading the biotech trade group. On the latest BioCentury This Week podcast. BioCentury Washington Editor Steve Usdin details Crowley’s plans to revitalize BIO at a time when effective representation in Washington is more important than ever, as well as has focus on biotech as a “national security imperative.”

BioCentury’s editors also discuss FDA’s landmark approval of a liver disease drug from  Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and the challenges the biotech faces in getting the THRβ agonist to patients with metabolic-associated steatohepatitis (MASH). The episode also delves into a decision by FDA’s Oncologic Drugs Advisory Committee to support a pair of BCMA-directed CAR T cell therapies in earlier lines to treat multiple myeloma, and what’s needed to help avoid deaths during the period while patient wait for the CAR T cells to be produced.

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please contact BioCentury at conferences@biocentury.com. To watch the latest BioCentury Show, which features a conversation with bioethicist Arthur Caplan visit BioCentury’s YouTube channel.